The MAPK/ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase) kinase (MEK) signalling cascade is a key regulator of cellular proliferation, differentiation and survival downstream of RAS activation. Upregulation of this pathway occurs in a large fraction of tumours. GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 with Ki value of 0.13 nM[3]. GDC-0623 up-regulated BIM (Bcl-2 Interacting Mediator of cell death) expression to a greater extent versus other MEK inhibitors in isogenic KRAS HCT116 and mutant KRAS SW620 colon cancer cells[1]. In KRAS-mutant cells, block of pMEK (phosphorylated MEK) accumulation caused by GDC-0623 (range: 0.00045–0.33 μM in threefold increments) resulted in more effective inhibition of pERK. MEK phosphorylation was blocked by CRAF and BRAF (V600E) in vitro in the presence of 0.01, 0.1 and 1 μM GDC-0623. In KRAS-mutant cells GDC-0623 at 0.1, 1 and 10 μM induced dimerization of MEK with both BRAF and CRAF. The average plasma concentration of GDC-0973 over 24 hours at its maximum tolerated dose (MTD) is 0.63 μM for GDC-0623. In KRAS-mutant xenograft model, superior antitumour activity was observed with GDC-0623 at its MTD[3].
作用机制
GDC-0623 forms a strong hydrogen-bond interaction with S212 in MEK[3].
GDC-0623 细胞实验
Cell Line
Concentration
Treated Time
Description
References
H23 cells
1 µM
24 hours
To study the effect of MAPK inhibitors on H23 cells, it was found that GDC-0623 did not significantly enhance HGF- and EGF-induced AKT phosphorylation.
Mol Cancer Res. 2016 Oct;14(10):1019-1029.
A549 cells
1 µM
24 hours
To study the effect of MEK inhibitors on KRAS-mutant lung cancer cells, it was found that MEK inhibitors including GDC-0623 enhanced HGF- and EGF-induced AKT phosphorylation.
Mol Cancer Res. 2016 Oct;14(10):1019-1029.
GDC-0623 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Nude mice
Colon cancer model COLO 205
Oral
40 mg/kg/day
Once daily for 14 days
GDC-0623 showed similar activity to BI-847325 in the BRAF V600E-mutated colon cancer model COLO 205, with tumor regression during the treatment period.
搜索
